TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.
Brief Summary: The primary purpose of this study is to determine the effects of a fixed dose combination of valsartan, hydrochlorothiazide, atorvastatin and aspirin (PolyPill) on prevention of cardiovascular events in adults older than 50.

Various liver-related variables will also be recorded which will allow studying the effects of PolyPill on the liver and the effect of liver diseases such as nonalcoholic steatohepatitis on cardiovascular events and the protective effect of PolyPill.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
B: Arm Label: GFT505 80mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 80mg | Arm Label: GFT505 120mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 120mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFT505 80mg; Assigned to Arm(s): GFT505 80mg | Intervention Type: DRUG; Name: GFT505 120mg; Assigned to Arm(s): GFT505 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
D: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.
Brief Summary: The primary purpose of this study is to determine the effects of a fixed dose combination of valsartan, hydrochlorothiazide, atorvastatin and aspirin (PolyPill) on prevention of cardiovascular events in adults older than 50.

Various liver-related variables will also be recorded which will allow studying the effects of PolyPill on the liver and the effect of liver diseases such as nonalcoholic steatohepatitis on cardiovascular events and the protective effect of PolyPill.


Options:
A: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
B: Arm Label: Polypill; Type: EXPERIMENTAL; Interventions: Drug: Polypill | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Polypill; Assigned to Arm(s): Polypill
C: Arm Label: Test and reference formulations; Type: EXPERIMENTAL; Interventions: Drug: Test formulation, Drug: Reference formulation | Intervention Type: DRUG; Name: Test formulation; Assigned to Arm(s): Test and reference formulations | Intervention Type: DRUG; Name: Reference formulation; Assigned to Arm(s): Test and reference formulations
D: Arm Label: Free combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: perindopril, indapamide , amlodipine | Arm Label: Tripliam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tripliam (perindopril, indapamide, amlodipine) | Intervention Type: DRUG; Name: perindopril, indapamide , amlodipine; Assigned to Arm(s): Free combination | Intervention Type: DRUG; Name: Tripliam (perindopril, indapamide, amlodipine); Assigned to Arm(s): Tripliam

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Brief Summary: ENABLE III is a randomized clinical trial that evaluates a phone-based palliative care intervention designed to improve quality of life, mood, and symptom management for patients with an advanced stage cancer and their caregivers.

The primary aims of this clinical trial are to determine whether a palliative care intervention (introduced immediately or 12 weeks after diagnosis) can improve survival, quality of life, mood, symptom intensity and end-of-life care.


Options:
A: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral
B: Arm Label: Specialised palliative care (SPC) group; Type: EXPERIMENTAL; Interventions: Other: Specialised palliative care (SPC) | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Specialised palliative care (SPC); Assigned to Arm(s): Specialised palliative care (SPC) group
C: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes
Brief Summary: ENABLE III is a randomized clinical trial that evaluates a phone-based palliative care intervention designed to improve quality of life, mood, and symptom management for patients with an advanced stage cancer and their caregivers.

The primary aims of this clinical trial are to determine whether a palliative care intervention (introduced immediately or 12 weeks after diagnosis) can improve survival, quality of life, mood, symptom intensity and end-of-life care.


Options:
A: Arm Label: Interventional arm; Type: EXPERIMENTAL; Interventions: Other: Interventional arm: Early best palliative care | Arm Label: Standard arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Interventional arm: Early best palliative care; Assigned to Arm(s): Interventional arm
B: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group
C: Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Other: early palliative care | Arm Label: early palliative care; Type: ACTIVE_COMPARATOR; Interventions: Other: early palliative care | Intervention Type: OTHER; Name: early palliative care; Assigned to Arm(s): control, early palliative care
D: Arm Label: early palliative care; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional palliative care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard oncologic care | Intervention Type: BEHAVIORAL; Name: Interventional palliative care; Assigned to Arm(s): early palliative care | Intervention Type: BEHAVIORAL; Name: Standard oncologic care; Assigned to Arm(s): Standard care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis
Brief Summary: The aim of the study is to establish whether treatment of superficial vein thrombosis (SVT) with low-molecular-weight heparin in preventive or therapeutic doses prevents disease progression and thromboembolic events (deep vein thrombosis and pulmonary embolism), whether efficacy of low-molecular-weight heparin differs with regard to the dosage used (prevention, treatment), and to recognize groups of patients in which treatment with heparin is most efficient, as well as to determine factors that influence the efficacy of SVT treatment with heparin.


Options:
A: Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin sodium injection | Intervention Type: DRUG; Name: Dalteparin sodium injection; Assigned to Arm(s): Ibuprofen
B: Arm Label: dalteparin 5000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Arm Label: dalteparin 15000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 5000 I.U./24 h s.c. | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 15000 I.U./24 h s.c.
C: Arm Label: Fondaparinux 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fondaparinux 2.5mg or placebo | Intervention Type: DRUG; Name: Fondaparinux 2.5mg or placebo; Assigned to Arm(s): Fondaparinux 2.5mg, Placebo
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Conservative, Plate Fixation and Prosthesis in Treatment of Displaced 2, 3, and 4 Part Fractures of Proximal Humerus of 60 Years and Older Patients
Brief Summary: This trial is designed to compare head-to-head conservative with operative treatment in 2 stratum. Stratum 1: In 2 part fractures the comparison is between conservative treatment and operative treatment with plate fixation with Philos. Stratum 2: In multi-fragmented fractures (MFF) meaning 3 and 4 part fractures, the comparison is between conservative treatment, operative treatment with Philos plate and operative treatment with Epoca prosthesis. Subgroup analysis will be performed in an effort to obtain limit values for specific treatment of different age and fracture groups. A cost-effectiveness analysis and comparison between different treatment modalities will be carried out. The primary outcome measure will be the DASH score and the secondary outcome measure the EQ-5D value. Recruitment period is 3 years and follow-up 2 years.


Options:
A: Arm Label: Operative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Operative treatment with Reversed Total Shoulder Prosthesis | Arm Label: Non-Operative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Operative treatment with Reversed Total Shoulder Prosthesis; Assigned to Arm(s): Operative treatment
B: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation (Physiotherapy) | Arm Label: Face-to-face intervention in a clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation (Physiotherapy) | Intervention Type: OTHER; Name: Rehabilitation (Physiotherapy); Assigned to Arm(s): Face-to-face intervention in a clinic, Telerehabilitation
C: Arm Label: Conservative; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Arm Label: Philos locking plate; Type: ACTIVE_COMPARATOR; Interventions: Device: Philos | Arm Label: Epoca prosthesis; Type: ACTIVE_COMPARATOR; Interventions: Device: Epoca | Intervention Type: DEVICE; Name: Philos; Assigned to Arm(s): Philos locking plate | Intervention Type: DEVICE; Name: Epoca; Assigned to Arm(s): Epoca prosthesis | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Conservative
D: Arm Label: Intervention Armeo®Spring; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention Armeo®Spring | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: Intervention Armeo®Spring; Assigned to Arm(s): Intervention Armeo®Spring | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Brief Summary: Specific Aim: To conduct a randomized, placebo-controlled trial of extended release-naltrexone (XR-NTX) among Human Immunodeficiency Virus (HIV) infected prisoners meeting Diagnostic Statistical Manual IV (DSM-IV) criteria for opioid dependence who are transitioning from the structure of a correctional setting to the community.

Hypotheses:

i. XR-NTX will result in improved HIV clinical outcomes, including lower changes in HIV-1 RNA levels, higher CD4 counts and higher rates of retention in care.

ii. XR-NTX will result in improved opioid treatment outcomes, including longer time to opioid relapse, lower addiction severity and lower craving for opioid.

iii. XR-NTX will result in reduced drug- and sex-related HIV risk behaviors compared to the control group.

iv. XR-NTX will result in decreased rates of reincarceration after 12 months of release to the community.


Options:
A: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1
C: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
D: Arm Label: Usual Case Management (UCM); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program | Arm Label: UCM + Smartphone; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program, Behavioral: Unlimited Smartphone | Arm Label: Smartphone Based Case Management (SPCM); Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program, Behavioral: Unlimited Smartphone, Behavioral: Smartphone Based Case Management (SPCM) app | Intervention Type: BEHAVIORAL; Name: In-Person Case Management at Homeless Recovery Program; Assigned to Arm(s): Smartphone Based Case Management (SPCM), UCM + Smartphone, Usual Case Management (UCM) | Intervention Type: BEHAVIORAL; Name: Unlimited Smartphone; Assigned to Arm(s): Smartphone Based Case Management (SPCM), UCM + Smartphone | Intervention Type: BEHAVIORAL; Name: Smartphone Based Case Management (SPCM) app; Assigned to Arm(s): Smartphone Based Case Management (SPCM)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Brief Summary: Specific Aim: To conduct a randomized, placebo-controlled trial of extended release-naltrexone (XR-NTX) among Human Immunodeficiency Virus (HIV) infected prisoners meeting Diagnostic Statistical Manual IV (DSM-IV) criteria for opioid dependence who are transitioning from the structure of a correctional setting to the community.

Hypotheses:

i. XR-NTX will result in improved HIV clinical outcomes, including lower changes in HIV-1 RNA levels, higher CD4 counts and higher rates of retention in care.

ii. XR-NTX will result in improved opioid treatment outcomes, including longer time to opioid relapse, lower addiction severity and lower craving for opioid.

iii. XR-NTX will result in reduced drug- and sex-related HIV risk behaviors compared to the control group.

iv. XR-NTX will result in decreased rates of reincarceration after 12 months of release to the community.


Options:
A: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo
B: Arm Label: Depot Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Depot naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: DRUG; Name: Depot naltrexone; Assigned to Arm(s): Depot Naltrexone | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): Placebo
C: Arm Label: DDMI-IGT; Type: EXPERIMENTAL; Interventions: Behavioral: Dual-diagnosis motivational interviewing (DDMI), Behavioral: Integrated group therapy (IGT) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Jail and community-based behavioral health services | Intervention Type: BEHAVIORAL; Name: Dual-diagnosis motivational interviewing (DDMI); Assigned to Arm(s): DDMI-IGT | Intervention Type: BEHAVIORAL; Name: Integrated group therapy (IGT); Assigned to Arm(s): DDMI-IGT | Intervention Type: BEHAVIORAL; Name: Jail and community-based behavioral health services; Assigned to Arm(s): Usual care
D: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supported Home-based Exercise Training Versus Usual Care After Cardiac Rehabilitation. A Randomized Controlled Study
Brief Summary: It is known that organized cardiac rehabilitation is effective in improving exercise capacity in coronary heart disease patients. Less is known about the long-term results after cardiac rehabilitation. Earlier studies have shown that many patients quit exercising when no longer attending formal rehabilitation. The investigators wish to investigate the effect of a maintenance program after ending a rehabilitation program, and to compare this to usual care. The investigators hypothesis is that the maintenance program will result in higher exercise capacity and more physical activity compared to usual care.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
B: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Maintenance program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Maintenance program | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: D